Loading stock…

BioNTech SE (BNTX) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

BNTXBioNTech

Revenue FY25$3.4B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-43%1

Revenue, next 1Y-41%1

Revenue, next 3Y, CAGR-6%1

Revenue, next 5Y, CAGR-1%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue fell 43%/yr over the last 3 years, and it is still set to shrink 6%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue fell 43%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to shrink 6%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to shrink 0.9%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

BNTXBioNTech

Total return Current181%

Price return Current181%

MOMENTUM RATING↗

WEAK27 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+2%7

YTD return+0%5

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return-10%3

3-year return-14%2

5-year return-61%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+2%).

WATCH

It's down 10% over the past year, now 23% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-3%) and so far this year (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -61% over five), behind 80% of the market.

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on BioNTech. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BNTXBioNTech

Revenue FY25$3.4B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-43%1

Revenue, next 1Y-41%1

Revenue, next 3Y, CAGR-6%1

Revenue, next 5Y, CAGR-1%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue fell 43%/yr over the last 3 years, and it is still set to shrink 6%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue fell 43%/yr over the last 3 years, behind 90% of companies worldwide.1/10

Revenue is set to shrink 6%/yr over the next 3 years, behind most of the market.1/10

Over five years revenue is set to shrink 0.9%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business whose decline is easing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

BNTXBioNTech

Total return Current181%

Price return Current181%

MOMENTUM RATING↗

WEAK27 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+2%7

YTD return+0%5

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return-10%3

3-year return-14%2

5-year return-61%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+2%).

WATCH

It's down 10% over the past year, now 23% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over the past month (-3%) and so far this year (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-14% over three years and -61% over five), behind 80% of the market.

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on BioNTech. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

BioNTech SE

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on BioNTech. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on BioNTech. Get the full investment case.

Premium